5-FC

AcronymDefinition
5-FC5-Fluorocytosine (antifungal agent)
References in periodicals archive ?
5-FC serum concentrations need to be closely monitored and trough levels must be maintained at approximately 40-80 [micro]g/ml.
We analyzed the T1-weighted DCE-MRI perfusion parameters ([K.sup.tr], [V.sub.p], and [[lambda].sup.tr]) and contrast enhancement measured at initiation and completion of NSC + 5-FC treatment and at one-month follow-up to evaluate changes in perfusion parameters and their correlation with overall survival of patients with recurrent high-grade glioma.
Previous studies have shown that the transduction of the cytosine deaminase ( CD ) gene into cancer cells followed by treatment with the prodrug 5-fluorocytosine (5-FC), is a successful suicide gene therapy strategy for various cancers.
When APS001 is administered in the presence of 5-FC, the CD enzyme expressed in solid tumors inherently facilitates the local conversion of 5-FC to 5-Fluorouracil (5-FU), an established anticancer agent, which results in the expression of anti-tumor effects.
This trial is a single-arm open-label Phase 1/2a trial evaluating the safety, pharmacokinetics and efficacy of repeated and ascending doses of TG6002 administered by IHA route in combination with oral 5-FC, a non-cytotoxic pro-drug that can be converted in 5-FU.
investigated the expression pattern of ten-eleven translocation proteins (TETs) which catalyze the oxidation of 5-mC to 5-hmC and further to 5-fC and 5-caC and the levels as well as the distribution of the 5-hmC, 5-fC, and 5-caC in postnatal neurons and adult neuronal stem cells (aNSCs).
This enzyme converts an inactive prodrug, 5-fluorocytosine (5-FC), to the chemotherapeutic effector 5-fluorouracil (5-FU) [2].
In vitro 48-hour to 72-hour MIC data in [micro]m/mL for the isolate were as follows: amphotericin B, >16; 5-flucytosine (5-FC), >64; ketoconazole, 0.5/0.5; fluconazole, 32/64; itraconazole, 0.5/0.5; clotrimazole, 0.06/0.25; voriconazole, 0.25/0.25; terconazole, 4/8; and posaconazole, 0.125/0.125.
This trial is a European single-arm open-label Phase 1/2 trial evaluating the safety and tolerability of multiple ascending doses of TG6002 administered intravenously in combination with oral 5-FC, a non-cytotoxic pro-drug that can be converted in 5-FU.
APS001F is a recombinant Bifidobacterium that expresses Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU.
It is an investigational treatment that is designed to program cancer cells to convert the prodrug 5-FC into the anticancer drug 5-FU, killing tumour cells and leading to activation of the immune system via a combination of mechanisms.